Cell-addictive dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway
文献类型:期刊论文
作者 | Li, YH; Chen, ZX; Lu, ZG; Yang, QH; Liu, LY; Jiang, ZT; Zhang, LQ; Zhang, X; Qing, H; Li, YanHui |
刊名 | THERANOSTICS |
出版日期 | 2018 |
卷号 | 8期号:19页码:5469 |
ISSN号 | 1838-7640 |
关键词 | Parkinson's Disease Blood-brain-barrier Dopaminergic Neurons Cocaine Binding-site Egcg Alpha-synuclein Nanoparticles Dopamine Transporter Alpha-synclein Aggregation Laminin Receptor Tea Polyphenol Potential Inhibitors Alzheimers-disease Mazindol Analogs Delivery |
DOI | 10.7150/thno.28295 |
文献子类 | Article |
英文摘要 | alpha-synclein (aS) aggregation is a representative molecular feature of the pathogenesis of Parkinson's disease (PD). Epigallocatechin gallate (EGCG) can prevent alpha S aggregation in vitro. However, the in vivo effects of PD treatment are poor due to the obstacles of EGCG accumulation in dopaminergic neurons, such as the blood brain barrier and high binding affinities between EGCG and membrane proteins. Therefore, the key to PD treatment lies in visual examination of EGCG accumulation in dopaminergic neurons. Methods: DSPE-PEG-B6, DSPE-PEG-MA, DSPE-PEG-phenylboronic acid, and superparamagnetic iron oxide nanocubes were self-assembled into tracing nanoparticles (NPs). EGCG was then conjugated on the surface of the NPs through the formation of boronate ester bonds to form a "cell-addictive" dual-target traceable nanodrug (B6ME-NPs). B6ME-NPs were then used for PD treatment via intravenous injection. Results: After treatment with B6ME-NPs, the PD-like characteristics was alleviated significantly. First, the amount of EGCG accumulation in PD lesions was markedly enhanced and traced via magnetic resonance imaging. Further, alpha S aggregation was greatly inhibited. Finally, the dopaminergic neurons were considerably increased. Conclusion: Due to their low price, simple preparation, safety, and excellent therapeutic effect on PD, B6ME-NPs are expected to have potential application in PD treatment. |
WOS记录号 | WOS:000450037900018 |
资助机构 | Beijing Municipal Science & Technology Commission [Z161100002616015] ; National Natural Science Foundation of China [81671268, 81701260] ; Brain cognition and brain medicine of Beijing Municipal Science & Technology Commission [Z161100002616020] ; National High Technology Research and Development Program [2016YFA0200303] ; Beijing Natural Science Foundation [L172046] |
源URL | [http://ir.ipe.ac.cn/handle/122111/26823] |
专题 | 中国科学院过程工程研究所 |
推荐引用方式 GB/T 7714 | Li, YH,Chen, ZX,Lu, ZG,et al. Cell-addictive dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway[J]. THERANOSTICS,2018,8(19):5469. |
APA | Li, YH.,Chen, ZX.,Lu, ZG.,Yang, QH.,Liu, LY.,...&Qing, Hong.(2018).Cell-addictive dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway.THERANOSTICS,8(19),5469. |
MLA | Li, YH,et al."Cell-addictive dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway".THERANOSTICS 8.19(2018):5469. |
入库方式: OAI收割
来源:过程工程研究所
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。